ANWPX
Price
$75.82
Change
+$0.08 (+0.11%)
Updated
Jun 2 closing price
Net Assets
164.3B
GLVIX
Price
$95.46
Change
+$0.61 (+0.64%)
Updated
Jun 2 closing price
Net Assets
591.68M
Interact to see
Advertisement

ANWPX vs GLVIX

Header iconANWPX vs GLVIX Comparison
Open Charts ANWPX vs GLVIXBanner chart's image
ANWPX vs GLVIX Comparison Chart in %
View a ticker or compare two or three
VS
ANWPX vs. GLVIX commentary
Jun 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANWPX is a Hold and GLVIX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
ANWPX has more cash in the bank: 164B vs. GLVIX (592M). ANWPX pays higher dividends than GLVIX: ANWPX (0.96) vs GLVIX (0.00). ANWPX was incepted earlier than GLVIX: ANWPX (53 years) vs GLVIX (14 years). GLVIX (0.87) is less costly to investors than ANWPX (0.71). ANWPX is a more actively managed with annual turnover of: 23.00 vs. GLVIX (17.00). ANWPX has a lower initial minimum investment than GLVIX: ANWPX (250) vs GLVIX (1000000). ANWPX annual gain was more profitable for investors over the last year : 14.01 vs. GLVIX (8.62). ANWPX return over 5 years is better than : 19.74 vs. GLVIX (14.93).
ANWPXGLVIXANWPX / GLVIX
Total Expense Ratio0.710.8782%
Annual Report Gross Expense Ratio0.710.8782%
Fund Existence53 years14 years-
Gain YTD7.26511.72062%
Front Load6%N/A-
Min. Initial Investment25010000000%
Min. Initial Investment IRAN/AN/A-
Net Assets164B592M27,703%
Annual Yield % from dividends0.960.00-
Returns for 1 year14.018.62162%
Returns for 3 years44.5647.8693%
Returns for 5 years19.7414.93132%
Returns for 10 years116.32132.4888%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MS214.983.97
+1.88%
Morgan Stanley
BBUC33.180.07
+0.21%
Brookfield Business Corp
ANAB51.22-1.92
-3.61%
AnaptysBio
FATE2.57-0.18
-6.39%
Fate Therapeutics
GRCE2.50-0.19
-7.06%
Grace Therapeutics Inc